Filtered By:
Specialty: Cardiology
Procedure: Dialysis
Therapy: Dialysis

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 322 results found since Jan 2013.

Visit-to-visit blood pressure variability is a risk factor for all-cause mortality and cardiovascular disease: a systematic review and meta-analysis
Conclusion: In summary, among the wide heterogenetic population, modest associations between VVV of SBP and all-cause mortality, CVD incidence, CVD mortality, CHD incidence, and stroke incidence were found. Findings of the current study suggested that standardized approaches of monitoring VVV in the high-risk population, including patients with cardiac infarction, diabetes, stroke, and patients with chronic kidney disease or in dialysis, are necessary in designing a prospective clinical study on the association of VVV and patients’ prognosis.
Source: Journal of Hypertension - December 1, 2016 Category: Cardiology Tags: Reviews Source Type: research

Editorial Commentary: Anticoagulation for atrial fibrillation in dialysis patients: What is known and what does the future hold?
The association between atrial fibrillation and stroke is well established and, in the general population, anticoagulation with warfarin can reduce the incidence of stroke by 60% with an acceptable bleeding risk.1, 2 Patients who are on hemodialysis have an increased prevalence of atrial fibrillation possibly secondary to comorbid conditions and hemodialysis itself causing dramatic swings in fluid and electrolytes and affecting cardiac dimensions.3 There are also substantially higher rates of ischemic stroke in this population attributable both to frequently co-occurring traditional stroke risk factors as well as the incre...
Source: Heart Rhythm - February 18, 2017 Category: Cardiology Authors: Timothy M. Markman, Saman Nazarian Source Type: research

Anticoagulation for atrial fibrillation in dialysis patients: What is known and what does the future hold?
The association between atrial fibrillation and stroke is well established, and in the general population, anticoagulation with warfarin can reduce the incidence of stroke by 60% with an acceptable bleeding risk.1,2 Patients who are on hemodialysis have an increased prevalence of atrial fibrillation, possibly secondary to comorbid conditions and hemodialysis itself causing dramatic swings in fluid and electrolytes and affecting cardiac dimensions.3 There are also substantially higher rates of ischemic stroke in this population attributable both to frequently co-occurring traditional stroke risk factors and to the increased...
Source: Heart Rhythm - February 18, 2017 Category: Cardiology Authors: Timothy M. Markman, Saman Nazarian Tags: Editorial Commentary Source Type: research

Comparison of different interdialytic intervals among hemodialysis patients on their echocardiogram-based cardiovascular parameters
Conclusions In a selective Japanese outpatient population on maintenance HD, there were no differences in resting cardiovascular function measured by echocardiography at 3 different IDTs. However, exercise-induced afterload mismatch assessed by the changes in Ea, SV, SW, and SW/PVA efficiency was most pronounced in individuals after the long IDT compared with other IDTs. Our findings report potential pathophysiologic echocardiographic parameters that attempt to explain why cardiovascular events are highest on the day after the long IDT compared to other IDTs in dialysis patients.
Source: American Heart Journal - March 10, 2015 Category: Cardiology Source Type: research

Visit-to-visit variability of blood pressure and death, end-stage renal disease, and cardiovascular events in patients with chronic kidney disease
Conclusion: Higher VVV of BP is independently associated with higher rates of death and hemorrhagic stroke in patients with moderate to advanced CKD not yet on dialysis.
Source: Journal of Hypertension - December 23, 2015 Category: Cardiology Tags: ORIGINAL PAPERS: BP measurement Source Type: research

The Atrial Fibrillation Conundrum in Dialysis Patients
Publication date: Available online 23 January 2016 Source:American Heart Journal Author(s): An S. De Vriese, Rogier Caluwé, Paolo Raggi The burden of atrial fibrillation (AF) and the risk of stroke are high in dialysis patients. The decision to use anticoagulation rests heavily on effective risk stratification. As both the pathophysiology of the disease and the response to therapy differ in dialysis, data from the general population cannot be extrapolated. The effect of vitamin K antagonists (VKA) on the risk of stroke in dialysis patients with AF has not been studied in randomized trials. The available observational...
Source: American Heart Journal - January 25, 2016 Category: Cardiology Source Type: research

Total aortic arch replacement using the thoraflex hybrid prosthesis: early- and medium-term results from a Scandinavian center
CONCLUSIONS: The Thoraflex hybrid prosthesis can be used in the setting of total aortic arch replacement with good early- and medium-term results. Stroke and spinal cord complications remain an important source of early mortality.PMID:34463180 | DOI:10.1080/14017431.2021.1970800
Source: Scandinavian Cardiovascular Journal - August 31, 2021 Category: Cardiology Authors: Maria D Soknes Per S Lingaas Runar Lundblad John-Peder Escobar Kvitting Source Type: research

A Pint of Sweat Will Save a Gallon of Blood: A Call for Randomized Trials of Anticoagulation in End Stage Renal Disease.
Abstract Approximately 430,000 patients were receiving maintenance dialysis in the United States in 2011(1). Compared to the general population, atrial fibrillation is far more common(2) and associated with a much higher risk of stroke in the dialysis population(3). Thus, there is an important need to define and apply strategies to reduce stroke in patients receiving dialysis with atrial fibrillation. PMID: 24452751 [PubMed - as supplied by publisher]
Source: Circulation - January 22, 2014 Category: Cardiology Authors: Granger CB, Chertow GM Tags: Circulation Source Type: research

Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Diabetes and Severe Aortic Stenosis at High Risk for Surgery An Analysis of the PARTNER Trial (Placement of Aortic Transcatheter Valve)
ConclusionsAmong patients with diabetes and severe symptomatic AS at high risk for surgery, this post-hoc stratified analysis of the PARTNER trial suggests there is a survival benefit, no increase in stroke, and less renal failure from treatment with transcatheter AVR compared with surgical AVR. (The PARTNER Trial: Placement of AoRTic TraNscathetER Valve Trial; NCT00530894)
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - March 17, 2014 Category: Cardiology Source Type: research

CKD Ups Stroke, Embolic Risk in Patients With AFCKD Ups Stroke, Embolic Risk in Patients With AF
The effect is especially great in patients on dialysis; warfarin anticoagulation still reduced mortality, however, at least in patients with non-end-stage renal disease. Heartwire
Source: Medscape Cardiology Headlines - December 8, 2014 Category: Cardiology Tags: Cardiology News Source Type: news

Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis.
CONCLUSIONS: -More dialysis patients are being started on dabigatran and rivaroxaban, even when their use is contraindicated and there are no studies to support the benefits outweigh the risks of these drugs in ESRD. PMID: 25595139 [PubMed - as supplied by publisher]
Source: Circulation - January 16, 2015 Category: Cardiology Authors: Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW Tags: Circulation Source Type: research

Comparison of Different Inter-dialytic Intervals Among Hemodialysis Patients on Their Echocardiogram-Based Cardiovascular Parameters
Conclusions In a selective Japanese outpatient population on maintenance hemodialysis, there were no differences in resting cardiovascular function measured by echocardiography at three different IDTs. However, exercise-induced afterload mismatch assessed by the changes in Ea, SV, SW and SW/PVA efficiency was most pronounced in individuals following the long IDT compared with other IDTs. Our findings report potential pathophysiologic echocardiographic parameters that attempt to explain why cardiovascular events are highest on the day after the long IDT compared to other IDTs in dialysis patients.
Source: American Heart Journal - February 13, 2015 Category: Cardiology Source Type: research

Randomized Controlled Trials of Blood Pressure Lowering in Hypertension: A Critical Reappraisal.
Abstract Sixty-eight blood pressure (BP)-lowering randomized controlled trials (defined as randomized controlled trials comparing active treatment with placebo, or less active treatment, achieving a BP difference, performed between 1966 and end 2013 in cohorts with ≥40% hypertensive patients, and exclusive of trials in acute myocardial infarction, heart failure, acute stroke, and dialysis) were identified and meta-analyzed grouping the randomized controlled trials on the basis of clinically relevant questions: (1) does BP lowering reduce all types of cardiovascular outcome? (2) Is prevention of all outcomes prop...
Source: Circulation Research - March 13, 2015 Category: Cardiology Authors: Zanchetti A, Thomopoulos C, Parati G Tags: Circ Res Source Type: research

Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction
ConclusionsTreatment with ACEI/ARB after AMI was associated with improved long-term survival, regardless of underlying renal function, and was accompanied by low rates of adverse renal events.
Source: Journal of the American College of Cardiology - April 4, 2016 Category: Cardiology Source Type: research

Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?
Abstract Heart failure in the setting of chronic kidney disease (CKD) is an increasingly common scenario and carries a poor prognosis. Clinicians lack tools for primary or secondary heart failure prevention in patients with cardiorenal syndromes. In patients without CKD, angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB) and statins mitigate cardiovascular risk in large part due to salutary effects on the endothelium. In the setting of CKD, use of these therapies is limited by adverse effects of hyperkalemia in pre-dialysis CKD (ACE-I/ARB), or potential increased risk of stroke...
Source: Current Heart Failure Reports - April 26, 2016 Category: Cardiology Source Type: research